antimicrobial drugs were discovered using this classical approach. However, the targets of 76 these drugs remained either unknown or were identified after several rounds of 77 experimentation. Alternatively, target based approach is used to identify inhibitors against 78 specific biochemical reaction or some important intermolecular interaction (3) . This is a 79 straight forward approach with high level of sensitivity and technologically more adaptive from 80 drug development perspective. Being mostly directed towards a well known target it allows 81 rationale-based optimization of lead molecules. However, it employs purely in vitro screening 82 methodologies and, therefore, the lead molecules are not tested for their penetration, efflux and 83 metabolic properties which are key druggable parameters. 84 In recent years, the whole-cell based screening was performed using genetically modified 85 bioluminescent strains which offered a good alternative to avoid these difficulties (4, 5, 6) . 86 developed using this strategy which allowed rapid in vitro screening of a large range of 91 antimycobacterial compounds (4, 5, 6, 7) , but one of the limitations of this system is that the 92 modes of action of leads remained unknown. The introduction of pathway-specific inducible 93 promoters allowed an enhanced expression of the reporter gene selectively in response to 94 inhibition of a certain biochemical pathway by a line of drugs (8, 9, 10, 11). The selective 95 induction of the reporter gene indicates that a compound is perturbing the pathway of interest at 96 some point, even if the inhibited targets are not known (8, 11) . This kind of screening system 97 renders advantage over others as they enable a systematic screening of compounds interfering 98 with a given metabolic pathway. However, a serious limitation of this approach is the inability 99 of the recombinant strains to identify even the more potent compounds if they are not acting 100 through the pathway of interest. Thus, these recombinant strains are reduced to merely a 101 second-line screening system and miss a large number of compounds effective against different 102 molecular targets and biochemical pathways.
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To overcome this problem, in this study, we have generated a double recombinant ethambutol (0.25µg/ml, 0.50µg/ml, 1.0µg/ml), streptomycin (0.50µg/ml, 1.0µg/ml, 2.0µg/ml), 169 INH (0.55µg/ml, 1.37µg/ml, 2.74µg/ml), rifampicin (0.50, 1.0µg/ml, 2.0µg/ml), vancomycin 170 (14.99µg/ml, 40µg/ml, 80µg/ml), polymyxin B (5.56µg/ml, 12.5µg/ml, 25µg/ml), ethionamide 171 (2µg/ml, 50µg/ml, 100µg/ml), thiolactomycin (20µg/ml, 35µg/ml, 75µg/ml), cerulenin 172 (3µg/ml, 4µg/ml, 8µg/ml) and triclosan (5µg/ml, 10µg/ml, 20µg/ml) and cultures were grown (rBCG) strains showed luciferase activity from early log phase to stationary phase ( Fig. 1 promoters are similar (Fig. 3) . This also ensured that the total luciferase activity is indeed with decline in RLU (Fig. 4) . We determined the percent inhibition of the bacterial growth inhibition profile was obtained through both approaches (Fig. 4) and Renilla luciferase in our assay. We performed dual luciferase assay using this strain after 
